{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:00:17Z","timestamp":1792047617460,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":704,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1111\/jth.15194","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T02:51:08Z","timestamp":1606272668000},"page":"58-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Should all patients with immune\u2010mediated thrombotic thrombocytopenic purpura receive caplacizumab?"],"prefix":"10.1016","volume":"19","author":[{"given":"Adrien","family":"Picod","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Veyradier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1111\/jth.15194_bb0010","doi-asserted-by":"crossref","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"6","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primer"},{"issue":"5","key":"10.1111\/jth.15194_bb0015","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2141.2008.07276.x","article-title":"Regional UK TTP Registry: correlation with laboratory ADAMTS 13 analysis and clinical features","volume":"142","author":"Scully","year":"2008","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1111\/jth.15194_bb0020","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/jth.12790","article-title":"Cardiac troponin\u2010I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"13","author":"Benhamou","year":"2015","journal-title":"J Thromb Haemost JTH"},{"issue":"5","key":"10.1111\/jth.15194_bb0025","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/S2352-3026(16)30018-7","article-title":"Epidemiology and pathophysiology of adulthood\u2010onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross\u2010sectional analysis of the French national registry for thrombotic microangiopathy","volume":"3","author":"Mariotte","year":"2016","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1111\/jth.15194_bb0030","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","article-title":"Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long\u2010term outcomes from 1995 through 2015","volume":"1","author":"Page","year":"2017","journal-title":"Blood Adv"},{"issue":"21","key":"10.1111\/jth.15194_bb0035","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1111\/jth.15194_bb0040","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/pbc.24612","article-title":"Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: Comparison of incidence, demographic and clinical features: TTP in children and adults","volume":"60","author":"Reese","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1111\/jth.15194_bb0045","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1111\/jth.15194_bb0050","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/rth2.12160","article-title":"Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine","volume":"3","author":"Coppo","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"10.1111\/jth.15194_bb0055","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.3324\/haematol.2011.049676","article-title":"Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency\u2010associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience","volume":"97","author":"Benhamou","year":"2012","journal-title":"Haematologica"},{"key":"10.1111\/jth.15194_bb0060","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single\u2010domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu Rev Biochem"},{"issue":"6","key":"10.1111\/jth.15194_bb0065","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/17512433.2019.1607293","article-title":"Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura","volume":"12","author":"Sargentini\u2010Maier","year":"2019","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1111\/jth.15194_bb0070","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/01.HS9.0000564208.56135.66","article-title":"Effect of plasma exchange on the pharmacokinetics and pharmacodynamics of caplacizumab: PS1287","volume":"3","author":"Sargentini","year":"2019","journal-title":"HemaSphere"},{"issue":"3","key":"10.1111\/jth.15194_bb0075","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1182\/blood-2010-11-317859","article-title":"Antithrombotic drug candidate ALX\u20100081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs","volume":"118","author":"Ulrichts","year":"2011","journal-title":"Blood"},{"issue":"17","key":"10.1111\/jth.15194_bb0080","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2012-04-420943","article-title":"Evaluation of efficacy and safety of the anti\u2010VWF nanobody ALX\u20100681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura","volume":"120","author":"Callewaert","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1111\/jth.15194_bb0085","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"380","key":"10.1111\/jth.15194_bb0090","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"9","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1111\/jth.15194_bb0095","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/jth.14679","article-title":"Efficacy and safety of open\u2010label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study","volume":"18","author":"Knoebl","year":"2020","journal-title":"J Thromb Haemost JTH"},{"issue":"10","key":"10.1111\/jth.15194_bb0100","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH Guidelines for Treatment of Thrombotic Thrombocytopenic Purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15194_bb0105","article-title":"A regimen with caplacizumab, immunosuppression and plasma exchange prevents unfavorable outcomes in immune\u2010mediated TTP","author":"Coppo","year":"2020","journal-title":"Blood"},{"issue":"13","key":"10.1111\/jth.15194_bb0110","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/bloodadvances.2020001973","article-title":"Real\u2010world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"4","author":"V\u00f6lker","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1111\/jth.15194_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA Reference Center Experience. Morty RE, editor","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"issue":"4","key":"10.1111\/jth.15194_bb0120","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1111\/jth.15194_bb0125","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH Guidelines for the Diagnosis of Thrombotic Thrombocytopenic Purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1111\/jth.15194_bb0130","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/ajh.24665","article-title":"Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: Causes of diagnostic errors and consequence on outcome. Experience of the French thrombotic microangiopathies reference center","volume":"92","author":"Grall","year":"2017","journal-title":"Am J Hematol"},{"issue":"13","key":"10.1111\/jth.15194_bb0135","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/bloodadvances.2020001987","article-title":"ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP","volume":"4","author":"V\u00f6lker","year":"2020","journal-title":"Blood Adv"},{"issue":"20","key":"10.1111\/jth.15194_bb0140","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long\u2010term relapses in immune\u2010mediated thrombotic thrombocytopenic purpura","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1111\/jth.15194_bb0145","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1111\/jth.15194_bb0150","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1111\/jth.15194_bb0155","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse","volume":"11","author":"Westwood","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15194_bb0160","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1111\/jth.15027","article-title":"Describing the point prevalence and characteristics of venous thromboembolism in patients with thrombotic thrombocytopenic purpura","volume":"18","author":"Tse","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15194_bb0165","article-title":"Venous thrombo\u2010embolism during immune\u2010mediated thrombotic thrombocytopenic purpura is prevalent in patients with a prolonged treatment with therapeutic plasma exchange","author":"Benhamou","year":"2020","journal-title":"Rev Med Interne"},{"issue":"10","key":"10.1111\/jth.15194_bb0170","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1111\/jth.15009","article-title":"Good Practice Statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1111\/jth.15194_bb0175","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMc1905426","article-title":"Caplacizumab therapy without plasma exchange for acquired thrombotic thrombocytopenic purpura","volume":"381","author":"Chander","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1111\/jth.15194_bb0180","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/trf.15823","article-title":"Caplacizumab for treatment of thrombotic thrombocytopenic purpura in a patient with anaphylaxis to fresh\u2010frozen plasma","volume":"60","author":"Irani","year":"2020","journal-title":"Transfusion"},{"issue":"11","key":"10.1111\/jth.15194_bb0185","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1111\/jth.15045","article-title":"Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab","volume":"18","author":"V\u00f6lker","year":"2020","journal-title":"J Thromb Haemost JTH"},{"issue":"24","key":"10.1111\/jth.15194_bb0190","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood.2019000748","article-title":"Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long\u2010term survival","volume":"134","author":"Prevel","year":"2019","journal-title":"Blood"},{"issue":"25","key":"10.1111\/jth.15194_bb0195","doi-asserted-by":"crossref","first-page":"6128","DOI":"10.1182\/blood-2011-09-380535","article-title":"A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13","volume":"119","author":"Schiviz","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1111\/jth.15194_bb0200","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1538-7836.2011.04224.x","article-title":"Recombinant ADAMTS13 normalizes von Willebrand factor\u2010cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies: rADAMTS13 overrides inhibitors in TTP plasma","volume":"9","author":"Plaimauer","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"16","key":"10.1111\/jth.15194_bb0205","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1182\/blood-2011-12-399501","article-title":"Gain\u2010of\u2010function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura","volume":"119","author":"Jian","year":"2012","journal-title":"Blood"},{"issue":"19","key":"10.1111\/jth.15194_bb0210","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS\u201013: first\u2010in\u2010human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1111\/jth.15194_bb0215","first-page":"226068","article-title":"Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura","volume":"105","author":"Gra\u00e7a","year":"2019","journal-title":"Haematologica"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15194","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15194","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622004585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622004585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:29:30Z","timestamp":1761535770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622004585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1538783622004585"],"URL":"https:\/\/doi.org\/10.1111\/jth.15194","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should all patients with immune\u2010mediated thrombotic thrombocytopenic purpura receive caplacizumab?","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15194","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}